Foresite Capital Management IV, LLC Diversified Active

Name: Foresite Capital Management IV, LLC Q4 2023 13F Filing | 13F Explorer
Creator: Foresite Capital Management IV, LLC
Published: 2024-02-13

Location: West Hollywood, CA

CIK: 0001704132 · Show all filings

Period: Q4 2023 (← Previous) (Next →)

Filing Date: Feb 13, 2024

Total Value: $198M (100.0% shares, 0.0% debt)

Holdings (5)

PHVS Pharvaris N.V. 57.3%

Value $113M Shares 4,038,842 Est. Cost $27.96 Unrealized -27.6%

KURA Kura Oncology, Inc. 13.4%

Value $26.6M Shares 1,849,947 Est. Cost $20.39 Unrealized -51.8%

— Kinnate Biopharma Inc. 11.6%

Value $22.92M Shares 9,671,643 Est. Cost $39.78 Unrealized —

SNDX Syndax Pharmaceuticals, Inc. 9.6%

Value $18.91M Shares 875,000 Est. Cost $22.62 Unrealized -32.1%

— Lyell Immunopharma, Inc. 8.2%

Value $16.15M Shares 8,325,000 Est. Cost $16.24 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	Pharvaris N.V.	4,038,842	$113M	57.3%	$27.96	-27.6%	COM	N69605108
KURA	Kura Oncology, Inc.	1,849,947	$26.6M	13.4%	$20.39	-51.8%	COM	50127T109
—	Kinnate Biopharma Inc.	9,671,643	$22.92M	11.6%	$39.78	—	COM	49705R105
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$18.91M	9.6%	$22.62	-32.1%	COM	87164F105
—	Lyell Immunopharma, Inc.	8,325,000	$16.15M	8.2%	$16.24	—	COM	55083R104